MEDITULIP, a Korean medical device company specializing in surgical instruments, has secured investment from Genaxis. Established in 2016 by Dr. Min-Woong Kang, a professor in the Thoracic Surgery Department at Chungnam National University Hospital, MEDITULIP focuses on developing advanced surgical devices such as endoscopic automatic staplers and implantable drug infusion devices (chemoports).

The company’s innovative endoscopic automatic staplers, Endo Stem and Endo Blossom, are the first in the world to adopt the Novel Asymmetrical Linear Stapler (NALS) mechanism. This unique design prevents excessive tissue resection, simplifies the detection of residual cancer cells, and eliminates the need for sutures after surgery. These advantages significantly reduce both operation and recovery times, earning widespread praise from medical professionals and patients alike.

Since July, MEDITULIP’s asymmetrical stapling devices have been used in clinical surgeries. In August of last year, they became the first endoscopic automatic staplers from a domestic company to receive certification and approval from the Ministry of Food and Drug Safety. Building on this achievement, the company is preparing to apply for FDA approval in the United States and plans to expand globally with its stapling technology.

In addition to its staplers, MEDITULIP has successfully localized the production of chemoports, a class IV medical device designed for cancer patients who require frequent injections. These coin-sized implantable devices are placed under the skin on one side of the chest and deliver medication directly through central veins. The company is now gearing up for commercial production.

Mi-kyung Son, CEO of Genaxis, remarked, “MEDITULIP possesses strong growth potential, driven by Dr. Kang’s clinical expertise and the company’s cutting-edge technology. We are confident that their FDA approval and global expansion will highlight the excellence and capability of Korean medical devices on the international stage.”

Dr. Min-Woong Kang, CEO of MEDITULIP, said, “Our growth has been guided by our founding mission of contributing to human happiness through technological innovation. Moving forward, we will continue to improve medical devices and dedicate ourselves to research and development aimed at enhancing patients’ quality of life.”